Prognostic Values of Coronary Artery Calcium Score and 123I-BMIPP SPECT In Patients With Non-Ischemic Heart Failure With Preserved Ejection Fraction

Hidenobu Hashimoto (✉ hidenobu.hashimoto@med.toho-u.ac.jp)  
Toho University Faculty of Medicine  https://orcid.org/0000-0003-2656-3445

Rine Nakanishi  
Toho University Faculty of Medicine

Sunao Mizumura  
Toho University Faculty of Medicine

Yukiko Hashimoto  
Toho University Faculty of Medicine

Yuriko Okamura  
Toho University Faculty of Medicine

Kyoko Ota  
Toho University Faculty of Medicine

Junichi Yamazaki  
Toho University Faculty of Medicine

Takanori Ikeda  
Toho University Faculty of Medicine

Research Article

Keywords: 123I-BMIPP SPECT, coronary artery calcium score, HFpEF, prognosis

DOI: https://doi.org/10.21203/rs.3.rs-206620/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose
This study aimed to determine whether coronary artery calcium score (CACS) can be a prognostic indicator for the development of major adverse cardiac events (MACEs) and compare the value of CACS with that of the $^{123}$I-betamethyl-p-iodophenyl-pentadecanoic acid ($^{123}$I-BMIPP) defect score (BDS) in patients with non-ischemic heart failure with preserved ejection fraction (NIHFpEF).

Methods
Among 643 consecutive patients hospitalized due to acute heart failure, 108 (74 ± 13y) were identified to have NIHFpEF on non-contrast regular chest computed tomography and $^{123}$I-BMIPP single-photon emission computed tomography (SPECT). We evaluated whether CACS and BDS were associated with MACEs using multivariate Cox models.

Results
Thirty-two MACEs developed at a mean follow-up period of 2.4 years. Higher CACS (hazard ratio [HR] 2.27, 95% confidence interval [CI] 1.10–4.67) and higher BDS (HR 22.14, 95% CI 7.95–61.60) were significantly associated with the development of MACEs. Patients showing higher CACS and BDS carried a significantly higher risk for developing MACE (HR 23.65, 95% CI 10.33–54.13, p < 0.001).

Conclusion
CACS, as well as BDS, could serve as potential prognostic indicators in patients with NIHFpEF.

Introduction
One in nine people die of heart failure (HF), and half the patients diagnosed as having HF die within 5 years [1]. Approximately half the patients with HF have preserved ejection fraction (HFpEF) [2]. Although considerable research efforts and funds have been devoted to improve mortality and reduce hospitalization, there has been no evidence-based treatment developed, to date, in patients with HFpEF [3].

The coronary artery calcium score (CACS), calculated using non-contrast regular chest computed tomography (CT), has recently been recognized as a prognostic marker for the assessment of cardiovascular event risk among asymptomatic patients [4]. The most common cause of HFpEF is diastolic HF, and the primary cause of diastolic HF is hypertensive heart disease [5]. Experimental and clinical data have demonstrated serological and morphometric evidence of increased myocardial fibrosis.
in patients with hypertensive heart disease [6, 7]. Therefore, HFpEF could be related to the progression of arteriosclerosis. However, the prognostic utility of CACS in patients with non-ischemic HFpEF (NIHFpEF) has not been well examined. On the other hand, $^{123}$I-betamethyl-p-iodophenyl-pentadecanoic acid single-photon emission computed tomography ($^{123}$I-BMIPP SPECT) plays an important role in the assessment of cardiovascular event risk in patients with coronary artery disease [8]. Although, in the clinical setting, the relationship between $^{123}$I-BMIPP defect score (BDS) and CACS of the patients with NIHFpEF, and clinical importance of them were unclear. Our previous study showed that $^{123}$I-BMIPP SPECT could be a useful modality for identifying high-risk patients with NIHFpEF [9]. In the present study, we aimed to investigate whether CACS is associated with the occurrence of major cardiac events (MACEs) and to compare the prognostic value of CACS with that of BDS in patients with NIHFpEF.

**Methods**

**Patient population**

Among 643 consecutive patients who were admitted to our hospital for congestive HF and underwent non-contrast regular chest CT to evaluate the presence of complication of pneumonia or quantity of pulmonary congestion and pleural effusion, $^{123}$I-BMIPP SPECT imaging to evaluate the presence of ischemic myocardial injury, echocardiography, and coronary artery angiography within 60 days between January 2010 and January 2014. We finally enrolled 108 patients with no obstructive coronary artery disease (<50% stenosis) on coronary artery angiography and had preserved ejection fraction ($\geq$ 50%) on echocardiography (Fig. 1). The patients’ clinical characteristics, including age, sex, coronary risk factors, blood biochemical data, echocardiography data, and medications were assessed. The institutional review board approved this retrospective study and the requirement to obtain informed consent was waived (M20136). This study was performed in accordance with the ethical standards of the Declaration of Helsinki.

**Invasive coronary angiography**

Invasive coronary angiography was performed for all participants. According to the American College of Cardiology/American Heart Association guidelines [10], quantitative coronary angiography was performed by experienced interventionalists. Coronary stenosis was defined as >50% diameter stenosis on invasive coronary angiography.

**Echocardiographic imaging**

Echocardiography from the parasternal window was performed to evaluate left ventricular function (Vivid E9 device, GE Vingmed, Horten, Norway). The Teichholz formula was used to calculate the left ventricular ejection fraction (LVEF) [11]. A LVEF >50% was defined as a preserved EF.

**Non-contrast non-cardiac chest CT**
Baseline CT scans were conducted with a 64-slice multidetector CT scanner (SOMATOM Definition Flash, Siemens, Munich, Germany). The scanning protocol consisted of the following parameters were applied: 28mm × 0.6 mm beam collimation, pitch 1.2, caudocranial scan direction, and smallest field of view to include the outer rib margins. No electrocardiographic triggering was performed, and no contrast agent was administered. Exposure settings were applied based on body weight: 125mAs at a tube voltage of 120 kVp.

All scans were reconstructed as 5.0 mm thick slices with an increment of 5.0 mm. Coronary artery calcium measurements were performed on a workstation (SYNAPSE VINCENT; FUJIFILM Medical Co., Ltd, Tokyo, Japan), and CACS was calculated using the Agatston scoring method [12].

**123I-BMIPP imaging**

123I-BMIPP (111MBq) was injected with the patients at rest. Twenty minutes later, 123I-BMIPP SPECT was performed over 360° in 72 steps of 37.5 s each in a 64 × 64 matrix, using a triple-head gamma camera (Prism IRIX; Philips, Amsterdam, Netherlands) equipped with low-energy general-purpose collimators. A Butterworth filter (order 8.0, cutoff value 0.25-0.30 cycle/pixel) and filtered back projection were used to process and reconstruct the images, respectively.

BDS was calculated according to a previously reported method [9], using an automated program for myocardial SPECT (Heart Risk View-S software; Nihon Medi-Physics Co Ltd, Tokyo, Japan). A hybrid 2-part sampling method [13], i.e., an algorithm for generating a polar map, was used to generate count profiles from a 3-dimensional sampling scheme of short-axis slices by operating in a 3-dimensional space and using short axis images. Then, polar maps were generated from 123I-BMIPP SPECT data divided into 17 segments to calculate the mean count in each segment, as recommended by the American Society of Nuclear Cardiology guidelines [14]. The mean counts in these segments were compared with references from the 123I-BMIPP database for Japanese patients which was developed by the Japanese Society of Nuclear Medicine working group [15]. The mean % uptake in each segment was derived and converted to scores using a five-point grading system (0, normal; 1, mildly reduced; 2, moderately reduced; 3, severely reduced; 4, absent). The BDS value in each segment was summed to obtain the total defect score in each patient.

**Assessment of clinical outcomes**

The endpoints were the development of MACEs (HF-related death, acute myocardial infarction, lethal ventricular arrhythmias, and other cardiac disorders), cardiovascular events (acute myocardial infarction and unstable angina), and severe HF requiring hospitalization. The diagnosis of acute myocardial infarction and unstable angina was based on standard laboratory findings, electrocardiograms, or examination criteria. Dyspnea, associated with pulmonary edema or congestion on chest radiograph, that required hospitalization was defined as HF exacerbation. The first event was included in the counting of clinical outcomes during the follow-up period. The event data were retrospectively gathered from the patients’ records, including in-hospital or out-of-hospital reports.
Statistical analysis

Data are expressed as average ± standard deviation of continuous variables. Continuous variables in patients with and without events were compared using the Mann-Whitney U test, and categorical data were analyzed using the chi-square test. To evaluate the clinical importance of CACS and BDS, all patients were divided into two groups based on their CACS values and BDS values. Each cutoff value was determined using the area under the curve (AUC) from a receiver operating characteristic (ROC) analysis based on MACE occurrences. The proportion of event-free patients was estimated using the Kaplan-Meier method and compared between each of the high and low CACS and BDS groups by using the log-rank test. Variables with a significance level of P-value < 0.05 in the univariate COX regression analysis were included in multivariate Cox regression models to determine whether the future occurrence of MACEs was associated with the parameters of echocardiographic imaging, CACS, or BDS. A P-value of < 0.05 was considered statistically significant. All statistical analyses were performed using StatMate V software version 5.01 (Advanced Technology for Medicine and Science, Tokyo, Japan).

Results

The patients’ characteristics, including coronary risk factors, New York Heart Association (NYHA) class, etiology of HF, B-type natriuretic peptide (BNP), LVEF calculated using echocardiography, CACS calculated using non-contrast non-cardiac chest CT, and BDS calculated using $^{123}$I-BMIPP SPECT are presented in Table 1. The mean age of the 108 patients was 74 ± 13 years, and 63 (58%) of them were men. Tachycardia-induced cardiomyopathy was the most common complication (n = 22, 20%). The other complications were valvular heart disease (n = 20), hypertensive heart disease (n = 19), atrioventricular block (n = 10), sick sinus syndrome (n = 7), dilated cardiomyopathy (n = 5), hypertrophic cardiomyopathy (n = 5), myocarditis (n = 3), pulmonary hypertension (n = 3), infective endocarditis (n = 2), and pulmonary thromboembolism (n = 2), respectively.
|                             | Total (n = 108, %) | MACE (n = 32, %) | No MACE (n = 76, %) | P value |
|-----------------------------|--------------------|------------------|---------------------|---------|
| Age (years)                 | 74 ± 13            | 76 ± 11          | 73 ± 14             | 0.455   |
| Male                        | 63 (58)            | 18 (56)          | 45 (59)             | 0.831   |
| Obesity (BMI > 25kg/m²)     | 20 (19)            | 6 (19)           | 14 (18)             | 0.786   |
| Diabetes mellitus           | 27 (25)            | 7 (22)           | 20 (26)             | 0.626   |
| Hypertension                | 76 (70)            | 25 (78)          | 51 (67)             | 0.356   |
| Dyslipidemia                | 36 (33)            | 12 (38)          | 24 (32)             | 0.655   |
| Current smoking             | 63 (58)            | 19 (59)          | 44 (58)             | 0.831   |
| CKD (eGFR < 60mL/min/1.73m²)| 59 (55)            | 20 (63)          | 39 (51)             | 0.290   |
| NYHA I/II/III/IV            | 24/27/30/27        | 5/7/9/11         | 19/20/21/16         | 0.184   |
| BNP                         | 710 ± 716          | 938 ± 929        | 613 ± 586           | 0.045   |
| **Complications**           |                    |                  |                     |         |
| Tachycardia-induced cardiomyopathy | 22 (20)          | 5 (16)           | 17 (22)             | 0.433   |
| Valvular heart disease      | 20 (19)            | 9 (28)           | 11 (14)             | 0.104   |
| Hypertensive heart disease  | 19 (18)            | 7 (22)           | 12 (16)             | 0.580   |
| Dilated cardiomyopathy      | 5 (5)              | 2 (6)            | 3 (4)               | 0.616   |
| Hypertrophic cardiomyopathy | 5 (5)              | 0 (0)            | 5 (7)               | 0.316   |
| **Echocardiography**        |                    |                  |                     |         |
| LVEF (%)                    | 64.9 ± 9.5         | 63.5 ± 8.4       | 65.5 ± 9.9          | 0.451   |
| LAD (cm)                    | 4.0 ± 0.1          | 4.5 ± 1.1        | 3.9 ± 0.9           | 0.010   |
| LVEDVI (ml/m²)              | 83.3 ± 32.0        | 91.8 ± 27.5      | 79.7 ± 33.2         | 0.039   |
| LVMI (g/m²)                 | 122.2 ± 40.1       | 130.5 ± 32.2     | 118.7 ± 42.7        | 0.047   |

MACEs = major adverse cardiac events; BMI = body mass index; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; NYHA = New York Heart Association; BNP = B-type natriuretic peptide; LVEF = left ventricular ejection fraction; LAD = left atrium dimension; LVEDVI = left ventricular end-diastolic volume index; LVMI = left ventricular wall mass index; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CT = computed tomography; CACS = coronary artery calcium score; $^{123}$I-BMIPP SPECT = $^{123}$I-betamethyl-p-iodophenyl-pentadecanoic acid single-photon emission computed tomography; BDS = $^{123}$I-BMIPP defect score.
MACEs = major adverse cardiac events; BMI = body mass index; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; NYHA = New York Heart Association; BNP = B-type natriuretic peptide; LVEF = left ventricular ejection fraction; LAD = left atrium dimension; LVEDVI = left ventricular end-diastolic volume index; LVMI = left ventricular wall mass index; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CT = computed tomography; CACS = coronary artery calcium score; $^{123}$I-BMIPP SPECT = $^{123}$I-betamethyl-p-iodophenyl-pentadecanoic acid single-photon emission computed tomography; BDS = $^{123}$I-BMIPP defect score.

Overall, 32 patients (30%) experienced MACEs during 2.4 ± 1.6 years of median follow-up. Cardiac deaths occurred in four patients (acute myocardial infarction in two patients, deterioration of HF in two patients), non-fatal acute myocardial infarction in one patient, and severe HF requiring hospitalization in 27 patients, respectively. Table 1 shows that BNP, left atrial dimension (LAD), left ventricular end-diastolic volume index (LVEDVI), left ventricular mass index (LVMI), CACS, and BDS were significantly higher in patients with MACEs. From the ROC analysis, the cutoff value for high BDS was 4 (AUC = 0.87), the cutoff value for high CACS was 68 (AUC = 0.69). Then, we determined the score of 100 was the cutoff value of CACS, since the score of 100 was commonly used for the risk stratification of coronary heart disease [16]. Of the 32 incidents of events, 17 cases occurred in the high CACS group. The proportion of patients who experienced MACEs was significantly higher in the high CACS group than in the low CACS group (Fig. 2). Of the 32 incidents of events, 26 cases occurred in the high BDS group. The proportion of patients who experienced MACEs was significantly higher in the high BDS group than in the low BDS group (Fig. 3). The Kaplan-Meier curves for MACEs in the combined groups of CACS and BDS are shown in Fig. 4. The proportion of patients who experienced MACEs was significantly higher in the high CACS and high BDS group than in the low CACS and low BDS group (7% vs. 78%, P < 0.001). In univariate analysis using categorical variables, BNP, CACS, and BDS were found to be the significant factors for MACEs (Table 2).
CACS and BDS were determined to be the significant prognostic factors of MACEs in each multivariate analysis model after adjusting for age, sex, and BNP (Table 3, models 1–3). In the multivariate Cox proportional model, the MACEs risk was significantly the highest in the high CACS and high BDS group (Table 3, model 4).

Table 2
Univariate Cox regression analysis for occurrence of MACEs

|                  | Univariate analysis | P value |
|------------------|---------------------|---------|
| **HR (CI)**      | **P value**         |
| Age (≥ 75)       | 1.160 (0.579–2.325) | 0.675   |
| Male             | 0.990 (0.491–1.993) | 0.977   |
| BNP (≥ 600)      | 2.179 (1.061–4.475) | 0.034   |
| LAD (>4cm)       | 1.752 (0.855–3.590) | 0.126   |
| LVEDVI (>75)     | 1.351 (0.660–2.764) | 0.410   |
| LVMI (>120)      | 1.939 (0.956–3.934) | 0.066   |
| CACS (≥100)      | 2.463 (1.222–4.966) | 0.012   |
| BDS (≥4)         | 17.995 (6.662–48.606) | <0.001 |

HR = hazard ratio; CI = confidence interval; other abbreviations as Table 1.
### Table 3
Multivariate Cox regression analysis for occurrence of MACEs

| Multivariate analysis | HR (CI)                     | P value  |
|-----------------------|-----------------------------|----------|
| **Model 1: echocardiographic imaging** |                            |          |
| LAD (> 4cm)           | 1.752 (0.854–3.596)         | 0.126    |
| LVEDVI (> 75)         | 1.407 (0.678–2.923)         | 0.360    |
| LVMI (> 120)          | 1.980 (0.972–4.032)         | 0.060    |
| **Model 2: $^{123}$I-BMIPP scintigraphy** |                            |          |
| BDS (≥ 4)             | 22.135 (7.954–61.596)       | < 0.001  |
| **Model 3: Non gated chest CT scan** |                            |          |
| CACS (≥ 100)          | 2.271 (1.104–4.672)         | 0.026    |
| **Model 4** |                                    |          |
| Low CACS, Low BDS group | 1 (ref)                  | -        |
| High CACS, Low BDS group | 2.644 (0.572–12.228)      | 0.389    |
| Low CACS, High BDS group | 12.078 (4.555–32.024)     | < 0.001  |
| High CACS, High BDS group | 23.646 (10.330–54.128)    | < 0.001  |

Abbreviations as in Table 1, 2. Model 1–3 adjusted for age, sex and BNP.

### Case presentations

Figure 5 shows a typical patient in the high CACS and high BDS group. This 72-year-old man had HF due to hypertensive heart disease (NYHA: class II, Nohria-Stevenson classification: wet and warm). He had a history of hypertension, diabetes mellitus, and hyperlipidemia. He also had a smoking habit. He underwent non-contrast non-cardiac chest CT for HF evaluation, and $^{123}$I-BMIPP SPECT, coronary artery angiography, and echocardiography owing to a suspicion of coronary heart disease. He had no coronary artery disease on coronary artery angiography, and his LVEF was 56% on echocardiography. His CACS was 1150.4, and his BDS was 7. In this case, the patient was admitted to the hospital because of HF deterioration at 210 days after non-contrast non-cardiac chest CT.

### Discussion

The findings of the present study demonstrated that CACS calculated using non-contrast regular chest CT was associated with an increase in MACEs and $^{123}$I-BMIPP SPECT findings, and that the evaluation of
CACS in addition to BDS had a predictive value for the identification of future MACEs in patients with NIHFpEF.

**HFpEF**

As patients with HFpEF are in a high-risk situation, it is essential that future cardiac risk be predicted using non-invasive imaging modalities. Echocardiography [17] and cardiac magnetic resonance imaging [18] have been shown to be useful in determining the outcomes of patients with HFpEF. In general, left ventricular diastolic dysfunction is recognized as a major pathophysiological abnormality [19]. Mechanisms underlying the development of HFpEF include endothelial dysfunction, myocardial hypertrophy, and myocardial fibrosis [20]. Endothelial dysfunction is reported to play an important role in the initial stage of atherosclerosis development [21, 22]. Atherosclerosis has been shown to be involved in the development of hypertension, accumulation of extracellular matrix material, and fibrosis within myocardial tissue [23]. More specifically, endothelial dysfunction initially causes atherosclerosis, leading to the development of hypertension, increase of extracellular matrix material, and fibrosis within myocardial tissue, which in turn results in left ventricular diastolic dysfunction. The present study demonstrated the potential of CACS to reflect the status of atherosclerosis, similar to a previous study which showed that BDS has the potential for reflecting the amount of extracellular matrix material and fibrosis within the myocardial tissue [9].

**Non-contrast non-cardiac chest CT**

The prognostic value of CACS calculated using cardiac CT has been evident across various population groups [24, 25]. Previous reports have shown that CACS by using non-contrast non-cardiac chest CT is a valid modality for determining CACS with an accuracy of up to 90%, compared with dedicated cardiac CT [26]. Hughes-Austin JM et al. reported that the CACS calculated using non-contrast non-cardiac chest CT is highly correlated with the CACS calculated using cardiac CT, and that the two scores are similarly associated with the mortality risk [27]. While the prognostic potential of CACS calculated using non-contrast non-cardiac chest CT in patients with HFpEF remains unexplored, this is the first study on the relationship between the prognostic value of CACS calculated using non-contrast non-cardiac chest CT and NIHFpEF. Our findings suggest that the evaluation of atherosclerosis could predict the grade of LV diastolic dysfunction and that could be able to predict the prognosis of HFpEF excepting for predicting of ischemic heart disease.

**Prognostic value of CACS in addition to BDS in patients with NIHFpEF**

In the current study, NIHFpEF patients in the high CACS and high BDS group showed the most significant association with cardiac events based on multivariate analysis. On the Basis of the mechanism of LV diastolic dysfunction development from endothelial dysfunction, BDS reflects early prognosis compared with CACS. The results shown in Fig. 2, 3, and 4 do not contradict this mechanism.
In the present study, high CACS and high BDS were associated with poor prognosis of cardiac events. The results suggest that BDS evaluation in addition to CACS evaluation enables early risk stratification in patients with NIHFpEF.

**Study limitations**

There are several limitations to this study. First, it had a relatively small sample size, which precluded the statistical reliability of the study. However, our results showed higher CACS and BDS to be significantly associated with the development of MACEs. Second, this study did not provide data on echocardiographic parameters, such as E/e', which may have an important implication for determining diastolic function. Instead, other diastolic parameters, such as LVEDVI and LVMI, were calculated as substitutes for diastolic parameters. Finally, this study was limited by the retrospective nature of the data obtained from non-contrast regular chest CT, $^{123}$I-BMIPP SPECT, echocardiography, and coronary artery angiography, as well as the outcomes of patients with NIHFpEF. Therefore, the timing of the imaging studies varied from patient to patient, and patient outcomes, which were reviewed based on the medical records, might have been incomplete. Further prospective studies with a larger number of participants are warranted to confirm the prognostic values of CACS and BDS in patients with NIHFpEF.

**Conclusion**

In this study, CACS demonstrated a high prognostic value for MACEs in patients with NIHFpEF. The evaluation of CACS in addition of BDS could have a predictive value for the identification of future MACEs in patients with NIHFpEF.

**Declarations**

**ACKNOWLEDGMENTS**

We are grateful to the radiology technologists Mr. Tadashi Kokubo, Mr. Kazuhiro Tachiki, Mr. Nobutomo Ishii, Mr. Takushi Okubo, and Mr. Fuyuki Washizuka for their technical assistance in the administration of $^{123}$I-BMIPP SPECT and chest CT.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**Compliance with ethical standards**

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Ethical approval**
The institutional review board approved this retrospective study and the requirement to obtain informed consent was waived (M20136).

Consent to participate and publish

Comprehensive agreement was obtained from all patients in the form of an opt-out on the institution's web-site.

Data and/or code availability

The data that support the findings of this study are available from the corresponding author.

Author contributions

All authors contributed to the study conception and design. Data collection and analysis were performed by Hidenobu Hashimoto, Rine Nakanishi, Yukiko Hashimoto, Yuriko Okamura and Kyoko Ota. Hidenobu Hashimoto performed the statistical analyses and drafted the manuscript. Sunao Mizumura, Junichi Yamazaki and Takanori Ikeda reviewed and revised the manuscript. All authors read and approved the final manuscript.

References

1. Go AS, Mozaffarian D, Roger VL et al (2014) Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129:399–410
2. Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259
3. Nanayakkara S, Kaye DM (2015) Management of heart failure with preserved ejection fraction: a review. Clin Ther 37:2186–2198
4. Peter CJ, Mathias P, Yolanda G et al (2010) Comparing Coronary Artery Calcium and Thoracic Aorta Calcium for Prediction of All-Cause Mortality and Cardiovascular Events on Low-Dose Non-Gated Computed Tomography in a High-Risk Population of Heavy Smokers. Atherosclerosis 209:455–462
5. Hogg K, Swedberg K, McMurray J (2004) Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:317–327
6. Brilla CG, Funck RC, Rupp H (2000) Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102:1388–1393
7. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512–2517
8. Matsuki T, Tamaki N, Nakata T et al (2004) Prognostic value of fatty acid imaging in patients with angina pectoris without prior myocardial infarction: comparison with stress thallium imaging. Eur J Nucl Mol Imaging 31:1585–1591
9. Hashimoto H, Nakanishi R, Mizumura S et al (2018) Prognostic Value of 123I-BMIPP SPECT in Patients with Nonischemic Heart Failure with Preserved Ejection Fraction. *J Nucl Med* 59:259–265

10. Scanlon PJ, Faxon DP, Audet AM et al (1999) ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol* 33:1756–824

11. Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 28:1–39

12. Agatston AS, Janowitz WR, Hildener FJ, Zusmer NR, Viamonte M, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol* 15:827–32

13. Garcia EV, Van Train K, Maddahi J et al (1985) Quantification of rotational thallium-201 myocardial tomography. *J Nucl Med* 26:17–26

14. Cerqueira MD, Weissman NJ, Dilsizian V et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 105:539–542

15. Nakajima K, Kumita S, Ishida Y et al (2007) Creation and characterization of Japanese standards for myocardial perfusion SPECT: database from the Japanese Society of Nuclear Medicine Working Group. *Ann Nucl Med* 21:505–511

16. Budoff MJ, Shaw LJ, Liu ST et al (2007) Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. *J Am Coll Cardiol* 49:1860–70

17. Donal E, Lund LH, Oqer E et al (2015) New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. *Eur J Heart Fail* 17:680–8

18. Mascherbauer J, Marzlufl BA, Tufaro C et al (2013) Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. *Circ Cardiovasc Imaging* 6:1056–1065

19. Zile MR, Gottdiener JS, Hetzel SJ et al (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. *Circulation* 124:2491–2501

20. Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 62:263–271

21. Ross R (1999) Atherosclerosis-an inflammatory disease. *N Engl J Med* 340:115–126

22. Higashi Y, Noma K, Yoshizumi M, Kihara Y (2009) Endothelial function and oxidative stress in cardiovascular disease. *Circ J* 73:411–418
23. Martos R, Baugh J, Ledwidge M et al (2007) Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. *Circulation* 115:888–895

24. Detrano R, Guerci AD, Carr JJ et al (2008) Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med* 13:1336–1345

25. Nakanishi R, Li D, Blaha MJ et al (2016) All-cause mortality by age and gender based on coronary artery calcium scores. *Eur Heart J Cardiovasc Imaging* 11:1305–1314

26. Kim SM, Chung MJ, Lee KS, Choe YH, Yi CA, Choe BK (2008) Coronary calcium screening using low-dose lung cancer screening: effectiveness of MDCT with retrospective reconstruction. *AJR Am J Roentgenol* 190:917–22

27. Hughes-Austin JM, Dominguez 3rd A, Allison MA et al (2016) Relationship of Coronary Calsium on Standard Chest CT Scans With Mortality. *JACC Cardiovasc Imaging* 2:152–9